DE3888269D1 - Hormon-Zusammensetzung und -Anwendung. - Google Patents

Hormon-Zusammensetzung und -Anwendung.

Info

Publication number
DE3888269D1
DE3888269D1 DE88308840T DE3888269T DE3888269D1 DE 3888269 D1 DE3888269 D1 DE 3888269D1 DE 88308840 T DE88308840 T DE 88308840T DE 3888269 T DE3888269 T DE 3888269T DE 3888269 D1 DE3888269 D1 DE 3888269D1
Authority
DE
Germany
Prior art keywords
application
progestin
estrogen
employs
short period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE88308840T
Other languages
English (en)
Other versions
DE3888269T2 (de
Inventor
Robert F Casper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jencap Research Ltd
Original Assignee
Jencap Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25671520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3888269(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 547744 external-priority patent/CA1332228C/en
Priority claimed from CA000547743A external-priority patent/CA1332227C/en
Application filed by Jencap Research Ltd filed Critical Jencap Research Ltd
Application granted granted Critical
Publication of DE3888269D1 publication Critical patent/DE3888269D1/de
Publication of DE3888269T2 publication Critical patent/DE3888269T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DE3888269T 1987-09-24 1988-09-23 Hormon-Zusammensetzung und -Anwendung. Expired - Lifetime DE3888269T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 547744 CA1332228C (en) 1987-09-24 1987-09-24 Formulation and method for estrogen replacement therapy
CA000547743A CA1332227C (en) 1987-09-24 1987-09-24 Oral contraceptive formulation

Publications (2)

Publication Number Publication Date
DE3888269D1 true DE3888269D1 (de) 1994-04-14
DE3888269T2 DE3888269T2 (de) 1994-07-07

Family

ID=25671520

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3856508T Expired - Lifetime DE3856508T2 (de) 1987-09-24 1988-09-23 Oestrogen und Progestin enthaltende Verhütungspackungen
DE3888269T Expired - Lifetime DE3888269T2 (de) 1987-09-24 1988-09-23 Hormon-Zusammensetzung und -Anwendung.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3856508T Expired - Lifetime DE3856508T2 (de) 1987-09-24 1988-09-23 Oestrogen und Progestin enthaltende Verhütungspackungen

Country Status (13)

Country Link
EP (2) EP0309263B1 (de)
JP (2) JP3314207B2 (de)
KR (1) KR0170764B1 (de)
CN (1) CN1042296C (de)
AT (1) ATE209919T1 (de)
AU (2) AU630334B2 (de)
DE (2) DE3856508T2 (de)
DK (1) DK174071B1 (de)
ES (2) ES2061672T3 (de)
FI (1) FI101601B1 (de)
HU (1) HU214598B (de)
NO (1) NO301689B1 (de)
NZ (1) NZ226316A (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738620A1 (de) * 1987-11-13 1989-05-24 Luderschmidt Christoph Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
AU8166191A (en) * 1990-08-10 1992-02-13 Ortho Pharmaceutical Corporation Method for treatment of bone wasting diseases
DE4104385C1 (de) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
EP0675720A1 (de) * 1992-12-28 1995-10-11 Jencap Research Limited Transdermale, mehrphasige hormonersatztherapie
HU228385B1 (en) * 1993-01-19 2013-03-28 Endorech Inc Use of dehydroepiandrosterone for the preparation of a medicament for the treatment of sexual disordes
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4405590C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonbehandlung
DE4405591C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonsubstitution
US5612317A (en) * 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
CA2261687A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
EP1007052B1 (de) * 1997-08-27 2004-10-13 Ortho-McNeil Pharmaceutical, Inc. Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE19831263A1 (de) * 1998-07-11 2000-01-13 Lohmann Therapie Syst Lts Darreichungsform
DE19911799A1 (de) * 1999-03-17 2000-09-28 Lohmann Therapie Syst Lts Sammelpackung zur Entnahme von befüllten Beuteln in vorgebener Reihenfolge
AU2005201151B2 (en) * 1999-03-30 2008-01-10 Jencap Research Ltd Low dose estrogen interrupted hormone replacement therapy
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
DE19934433A1 (de) 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
PL353994A1 (en) * 1999-08-31 2003-12-15 Jenapharm Gmbh & Co.Kgjenapharm Gmbh & Co.Kg Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
DE60307602T2 (de) * 2002-03-11 2007-10-04 Janssen Pharmaceutica N.V. Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie
ATE345804T1 (de) * 2002-08-28 2006-12-15 Robert Casper Estrogenersatztherapie
HUP0301981A2 (hu) * 2003-06-30 2005-04-28 Richter Gedeon Vegyészeti Gyár Rt. Tiszta d-(17alfa)-13-etil-17-hidroxi-18,19-dinor-pregn-4-én-20-in-3-on-3E- és 3Z-oxim izomerek, valamint eljárás az izomer keverékek és a tiszta izomerek előállítására
US7576226B2 (en) 2003-06-30 2009-08-18 Richter Gedeon Vegyeszeti Gyar Rt. Process of making isomers of norelgestromin and methods using the same
EP1535618A1 (de) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmazeutische Zubereitung zur kontinuierlichen hormonellen Behandlung über einen Zeitraum von über 21-28 Tage beinhaltend zwei Estrogen und/oder Progestin Zusammensetzungen
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
PE20060378A1 (es) * 2004-07-07 2006-06-02 Wyeth Corp Regimenes y kits de progestina ciclica
JP2014508784A (ja) * 2011-03-25 2014-04-10 ユニヴェルシテ ラヴァル １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3568828A (en) * 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3836651A (en) * 1972-02-22 1974-09-17 Biolog Concepts Inc Novel oral contraceptive combination
DE2645307A1 (de) * 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
US4291028A (en) * 1977-12-30 1981-09-22 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4292315A (en) * 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
FR2589735A1 (fr) * 1985-11-07 1987-05-15 Beillon Xavier Compositions anticonceptionnelles contenant un oestrogene et un progestatif
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women

Also Published As

Publication number Publication date
FI101601B (fi) 1998-07-31
AU630334B2 (en) 1992-10-29
DK529688A (da) 1989-05-25
KR0170764B1 (ko) 1999-02-01
HUT50043A (en) 1989-12-28
NO884230D0 (no) 1988-09-23
AU2276088A (en) 1989-04-06
ES2061672T3 (es) 1994-12-16
JPH01132523A (ja) 1989-05-25
NO301689B1 (no) 1997-12-01
FI884378A (fi) 1989-03-25
EP0559240B1 (de) 2001-12-05
JP3314207B2 (ja) 2002-08-12
NO884230L (no) 1989-03-28
DK529688D0 (da) 1988-09-23
ES2169030T3 (es) 2002-07-01
NZ226316A (en) 1991-10-25
FI101601B1 (fi) 1998-07-31
IE20030160A1 (en) 2003-07-09
EP0309263B1 (de) 1994-03-09
AU3044892A (en) 1993-02-11
CN1042296C (zh) 1999-03-03
EP0559240A3 (en) 1993-12-22
HU214598B (hu) 1998-04-28
JP3208482B2 (ja) 2001-09-10
DE3856508D1 (de) 2002-01-17
DE3856508T2 (de) 2002-06-06
DK174071B1 (da) 2002-05-21
EP0309263A3 (en) 1989-08-02
CN1041528A (zh) 1990-04-25
JPH11286446A (ja) 1999-10-19
EP0559240A2 (de) 1993-09-08
FI884378A0 (fi) 1988-09-23
EP0309263A2 (de) 1989-03-29
DE3888269T2 (de) 1994-07-07
ATE209919T1 (de) 2001-12-15
KR890004723A (ko) 1989-05-09

Similar Documents

Publication Publication Date Title
DE3888269D1 (de) Hormon-Zusammensetzung und -Anwendung.
AU560487B2 (en) Contraceptive comprising gestodene and ethinylestradiol
PT748190E (pt) Metodos e formulacoes para uso no tratamento de disturbios ginecologicos benignos
ATE75401T1 (de) Kombinations-dosierform fuer frauen in der praemenopause.
FI922206A0 (fi) Osmotisk, oral doseringsform foer fertilitets kontroll.
BG104451A (en) Antiestrogen and progestin-containing peroral contraceptives
AP2001002054A0 (en) Use of biogenic estrogen sulfamates for hormone replacement therapy.
NZ304027A (en) Once a month injectable contraceptive comprising an estrogenic and gestagenic component for contraception and simultaneous hormone replacement therapy

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings